Genetic modification of T lymphocytes with T-cell receptor (TCR) genes provides a novel tool for adoptive immunotherapy. However, the efficiency of full-length TCR (flTCR)-transduced T cells could be limited by factors such as incorrect pairing between exogenous and endogenous TCR chains and downregulation of the CD3 complex. To overcome these hurdles, one promising strategy is to use three-domain single-chain TCRs (3D-scTCR), in which TCR Va and Vb chains are joined by a linker with signal transduction domains fused at the carboxyl termini as signal transducers and amplifiers. Our results showed that surface expression of scTCRs on T cells after retroviral transduction was affected by the origin of the transmembrane (TM) region and placement of signaling domains. scTCR-modified T cells were functional as shown by cytokine (IL-2 and IFN-g) release in response to antigen stimulation and cytolytic activity against specific target cells. CD8 and CD28, but not the complete CD3 complex, could enhance the scTCR-induced T cell activation. Compared with flTCR-modified T cells and native CTLs, scTCR-modified T cells require higher thresholds of antigen stimulation (B10 À8 M peptide) to be functional. Despite the low efficiency of scTCRs, our data provide insight into further improvements in generating efficient scTCRs for in vivo applications.
A doptive transfer of T cells genetically modified with immunoreceptors, such as T-cell receptor (TCR) and single-chain antibody (T-body), has emerged as a promising approach to redirect specific immunity towards tumors and viral infections. [1] [2] [3] [4] [5] [6] [7] [8] This strategy avoids the limitations of the low frequency of antigen-specific T cells, allowing for facilitated expansion of antigen-specific T cells to therapeutic doses. 7, 8 In the majority of TCR-based studies, full-length TCRs (flTCRs) have been used. [6] [7] [8] [9] [10] [11] However, the efficiency of flTCR-modified T cells could be compromised by several factors. First, incorrect chain pairing between endogenous and transgenic TCR molecules plus possible instability of exogenous TCR a chains might result in suboptimal expression of the desired TCR heterodimers. 6, 12 Second, the incorrect a and b chain pairings might alter the TCR antigen recognition specificity leading to autoimmunity. 10 Third, the CD3z chain, which is required for surface expression of the TCR complex, [13] [14] [15] has been reported to be downregulated in cancer patient T cells, 16 thus limiting the functional efficiency of full-length transgenic TCRs.
One promising solution to these problems is the use of three-domain single-chain TCRs (3D-scTCR), in which the TCR Va and Vb chains are joined by a flexible linker with signal transduction domains fused at the carboxyl termini as signal transducers and amplifiers. 5, 12, 17 Although many efforts have been made to construct and characterize scTCRs, most studies have focused on Escherichia coli and yeast expression systems. [18] [19] [20] [21] Knowledge of the immunological consequences of engineering T cells with scTCR constructs remains limited. To date, no systematic study has been undertaken to elucidate as to which factors affect scTCR function such as placement of transmembrane (TM) region and signaling domains, and the need for coreceptor CD8, costimulatory receptor CD28, and the complete CD3 complex in scTCR-induced T-cell activation.
To address these issues, multiple scTCR constructs were made, derived from chicken ovalbumin (OVA)-specific H-2K b -restricted TCR. Variations in these constructs focused on the use of different TM region and intracellular signaling (CD3z, CD28 and p56
Lck ) domains. After transferring scTCR constructs into both a mouse T-cell line (BW5147) as well as primary T cells via retroviral transduction, it was possible to show that scTCR could be efficiently expressed on the cell surface if the viral titer was high enough (410 7 CFU/ml). scTCR surface expression was affected by the TM region and placement of signaling domains. When cocultured with OVA 257-264 peptide pulsed EL-4 cells, scTCR-modified T cells could produce cytokines (IL-2 and IFN-g) and lyse target cells. Integration of CD3z and CD28 with or without p56
Lck in the same 3D-scTCR molecule allowed stronger signaling than constructs with CD3z alone. CD8, CD28 and the complete CD3 complex were not required for the scTCR function. However, CD8 and CD28 could significantly increase the response of scTCR-modified T cells to antigen stimulation. Despite multiple optimizations, scTCR-modified T cells were less efficient in response to stimulation with low concentrations (10 À10 M) of OVA peptide-pulsed EL-4 cells and OVAexpressing EG7 cells as compared to flTCR-engineered T cells. Possible low-affinity binding of scTCRs might play a role in the higher activation threshold of scTCRmodified T cells.
Materials and methods

Cell lines
GP-293 packaging cells were purchased from Clontech (Palo Alto, CA). The packaging cell line GP þ E-86, mouse T-cell lymphoma BW5147, EL-4 (thymoma), OVA-expressing EL-4 clone EG7 22 and mouse fibroblast NIH/3T3 were purchased from the American Type Culture Collection (ATCC, Rockville, MD). All cell lines were cultured in Dulbecco's modified Eagle medium with a high glucose concentration (4.5 g/l) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Hyclone, Logan, UT), 100 U/ml penicillin, 100 mg/ml streptomycin and 2 mM L-glutamine.
Plasmid construction
All scTCR constructs were made in a cassette fashion (see Fig 1) . Briefly, TCR portions and signal transduction domains were constructed separately, ligated and introduced into LXSN (a gift from Dr Dusty A Miller, Fred Hutchinson Cancer Research Center, Seattle, WA) at the EcoRI site. The fragments Va2-Ja23 (nucleotides 1-420, primers #1 and 2) and Vb5.2-DJb2.3-Cb (nucleotides 88-804, Cb stops just before the cysteine, primers #7 and 8) were amplified by PCR using the plasmid TCR70 23 (a gift from Dr Larry Pease, Mayo Clinic at Rochester) as a template. The sequences of PCR primers are shown in Table 1 . The plasmid TCR70 contains the OVA-specific, full-length TCR genes coding for both a and b chains. The a and b chain PCR fragments were joined with a universal (Gly 4 Ser) 3 linker (G4S) 3 . 24 In constructs scTCR-Cys-z, scTCR-Cb-z and scTCR-Cb-28-z-Lck, either the cysteine residue (nucleotides 805-807, primers #7 and 9) or the Cb region extending to the transmembrane domain (nucleotides 805-930, primers #7 and 10) was included. The mature CD3z chain (nucleotides 64-492, primers #14 and 16) and CD3z cytoplasmic tail sequences (nucleotides 154-492, primers #15 and 16) were derived from the fulllength mouse CD3z chain cDNA (obtained from Dr Allan M Weissman, NIH, Bethesda, MD) by PCR. In scTCR-28-z and scTCR-28-z-Lck, the DNA sequence encoding amino acids 117-199 of mature mouse CD28 including the hinge region, transmembrane domain and cytoplasmic tail was amplified by PCR (primers #19 and 23 or 24) from a plasmid containing the full-length CD28 (kindly provided by Dr James P Allison, University of California at Berkeley, CA). In scTCR-z-28, scTCR-z-28-Lck and scTCR-Cb-28-3z-Lck, only the CD28 cytoplasmic tail sequence (nucleotides 535-654, primers #20 and 24 or 21 and 23) was used. The CD28-CD3z-Lck fragment in scTCR-Cb-CD28-CD3z-Lck was generated by PCR (primers #20 and 25) using H-2K Transgenic TCR expression T Zhang et al (Clontech, Palo Alto, CA) and pFB-neo (Stratagene, La Jolla, CA), respectively. The full-length TCR a and b chain were generated by PCR (TCR a chain: primers #3 and 4; TCR b chain: primers #5 and 6) using the plasmid TCR70 as a template and then inserted into the XhoI/Sall sites of the SAMEN vector (a gift from Dr Michael Nishimura, University of Chicago, IL). Full-length CD3d and z chain cDNAs were amplified (CD3d chain: primers #30 and 31; CD3z chain: primers #13 and 16) using the plasmid pCD-mCD3d (a gift from Dr Cox Terhorst, Harvard Medical School, Cambridge, MA) and pGEMCD3z, respectively. Construction of a mouse CD3d and z chain coexpressing vector, SAMEN-CD3zd, was performed similar to that of SAMEN-TCRba. The sequences of all PCR amplified fragments were confirmed by sequencing.
Retrovirus production and transduction
At 18 hours before transfection, GP-293 cells were plated in six-well plates at a density of 8 Â 10 5 cells per well in 2 ml. In order to increase the adhesion of GP-293 cells, plates were precoated with 0.01% poly-L-lysine (P6282, Sigma) in accordance with the manufacturer's instruction. Transfection of retroviral constructs into GP-293 cells was performed using GenePORTOR2 (Gene Therapy System, San Diego, CA). Briefly, 1 mg VSV-G expressing plasmid pVSV-G (Clontech, Palo Alto, CA) plus 1 mg retroviral constructs were complexed with 10 ml Gene-PORTOR2 and added directly to plates. After 24 hours, 1 ml fresh DMEM-10 was added. Viral supernatants were collected 48 and 72 hours post transfection and filtered (0.45 mm). The VSV-G pseudotyped viruses were used to transduce the ecotropic packaging cell GP þ E-86 in the presence of polybrene (8 mg/ml). After three rounds of transduction, GP þ E-86 cells were selected in G418 (1 mg/ml) for 7 days. Through this process, the virus titer from pooled GP þ E-86 cells generally was over 1 Â 10 6 CFU/ml. Concentration of retroviruses by polyethylene glycol (PEG) was performed according to a method described previously 26 except that virus supernatants were centrifuged at 2000 g (Beckman GPR, B3200 r.p.m.), 41C for 15 minutes. Viral stocks with high titer (1-2 Â 10 7 CFU/ml) were used for transduction of T cells. BW5147 cells were transduced three times (once a day on 3 consecutive days), whereas primary T cells from spleens of C57BL/6 (B6) mice were infected only once 18-24 hours after concanavalin A (ConA, 2.5 mg/ml) stimulation based on our previous protocol. 26 At 3 days after infection, transduced primary T cells (0.5-1 Â 10 6 /ml) were selected in RPMI-10 media containing G418 (600 mg/ ml) plus 25 U/ml rHuIL-2 for additional 5 days. Viable cells were isolated using Lympholyte-M (Cedarlane Laboratories, Hornby, Canada) and expanded for 2 days without G418 before functional analyses.
Cytokine production by TCR-modified T cells ) was set up in the same way. Before incubation at 371C, plates were centrifuged at 450 g for 5 minutes to initiate close cell contact. After 24 hours, supernatants were collected. IL-2 and IFN-g were assayed by ELISA using murine IL-2 and IFN-g ELISA kits (BD Pharmingen, San Diego, CA), respectively. Mock-transduced T cells were used as negative controls and T cells from OT1 mice (OVA 257-264 -specific TCR transgenic mice, strain name: C57BL/6-Tg(TcraTcrb)1100Mjb, Jackson Lab) served as positive controls.
Flow cytometry
The detection of scTCR surface expression on GP þ E86 and BW5147 cells was performed using an FITC-anti-TCR b chain mAb H57-597 (Caltag, Burlingame, CA). Before staining, GP þ E86 cells were detached from plates using 0.02% trypsin plus EDTA. Cell-surface phenotyping of transduced cells was determined by direct staining with PE-anti-CD8a (clone 53-6.7, Caltag), PE-anti-CD80 (clone 16-10A1, Caltag), PE-anti-CD28 (Clone, Caltag), FITC-anti-TCR Vb5 (clone MR9-4, Pharmingen) and PE-anti-TCR Va2 (clone B20.1, Pharmingen) mAbs. Cell fluorescence was monitored using an Epics XL flow cytometer (Beckman Coulter, Inc., Miami, FL). Cell sorting was performed on a Becton Dickinson FACStar (Franklin Lakes, NJ).
Cytotoxicity assay
At 3 days before CTL activity was assayed, TCRmodified primary T cells were restimulated with mitomycin-C treated, OVA peptide-pulsed (10 À6 M) stimulator splenocytes in RPMI-10 containing 25 U/ml IL-2. OVA peptide loading was performed at 371C for 2 hours and washed twice before use. After restimulation, viable lymphocytes were recovered by centrifugation over Lympholyte-M and washed. EG7 and OVA peptidepulsed EL-4 were used as target cells. Effector cells (1 Â 10 5 ) and target cells (1 Â 10 4 ) were added to each well of 96-well U-bottom culture plates. Plates were incubated at 371C for 5 hours, and supernatants were recovered. Specific lysis was measured with the nonradioactive CytoTox 96 kit (Promega, Madison, WI) according to the manufacturer's instructions.
Results
Surface expression of single-chain and full-length TCR
To investigate systematically the effects of scTCR structure on membrane expression, antigen recognition and T-cell activation, nine recombinant scTCRs were made (Fig 1a) . These scTCRs differed in TM regions from different origins (TCR Cb, CD3z and CD28 and B7.1) and combination of signal transduction domains (CD3z, CD28 and p56 Lck ). scTCR surface expression was first determined on the NIH-3T3-derived packaging cell, GP þ E86. Since packaging cells generally contain multiple copies of retroviral constructs and copy number can increase over time 27 this approach is a sensitive platform to study chimeric receptors' display. As shown in Figure 2a , CD3z(TM)-, CD28(TM)-and B7.1(TM)-containing scTCRs (except scTCR-z-28) could be efficiently expressed on GP þ E86 cells as determined using the pan-TCR antibody H57. Anti-Va2 mAb B20 and antiVb5 mAb MR9-4 gave similar results as the H57 mAb (Fig 2c) . Inclusion of a cysteine residue at the hinge region of scTCR-z had no significant effect on the surface expression. When the hinge and TM regions of wild-type TCR Cb chain were kept in the scTCRs, the surface expression was relatively low. As shown in Figure 2b , scTCRs could be expressed on the CD3d and z chains double negative T-cell line BW5147. 28 Unlike the scTCRs whose expression was controlled by a single promoter, the long terminal repeat (LTR) from murine leukemia retroviruses (MuLV), simultaneous expression of flTCRs requires both the TCR a and b chains to be driven under two separate promoters (Fig  1b) . To achieve the coexpression purpose, the SAMEN vector was used. This vector has been reported to be efficient in directing gene expression of both TCR a and b chains on the same vector. [6] [7] [8] In order to restore the expression of CD3d and z genes, which are required for the surface expression of the TCR-CD3 complex, [13] [14] [15] 28 a vector (SAMEN-CD3dz) for coexpression of both CD3d and z genes was made. After CD3d, z and flTCR genes were cotransduced into BW5147 cells three times; more than 80% of BW5147 cells were detected positive using the H57 mAb (Fig 2b) . Figure 3a . scTCR-transduced BW5147 cells produced a large amount of IL-2 in response to OVA 257-274 peptide stimulation at higher concentrations (10
À6
-10 À4 M) (see Fig 3b) . However, when the OVA 257-264 peptide concentration was lowered to 10 À8 M, no significant IL-2 production was observed in any of the scTCR-expressing BW5147 cells. In contrast, flTCRreconstituted BW5147 cell could respond to OVA [257] [258] [259] [260] [261] [262] [263] [264] peptide stimulation at concentrations as low as 10 À10 M. However, control TRP2 peptide-pulsed EL-4 cells failed to stimulate TCR-modified BW5147 cells to produce significant amounts of IL-2 (data not shown). The effects of the CD8 coreceptor and CD3 complex on scTCRinduced activation were investigated by transducing the CD8a and CD3dz genes into scTCR-modified BW5147 cells, respectively. CD8aa expression could increase the maximal IL-2 production by 30-300%. Restoration of CD3d and z expression in BW5147 cells had no significant effect on scTCR-induced IL-2 production. Integration of CD3z and CD28 with or without p56
Lck in the same 3D-scTCR allowed a one-fold increase in maximal IL-2 production than seen with CD3z alone in the presence of CD8aa. Interestingly, IL-2 production by BW5147 cells modified with CD28(TM)-containing scTCRs (scTCR-28-z and scTCR-28-z-Lck) dropped more sharply than that modified with CD3z(TM)-containing scTCRs when the OVA 257-264 peptide concentration was within the range of 10 -4 -10 À6 M. The contribution of costimulatory receptor CD28 on scTCR-induced T-cell activation was evaluated using B7.1-transduced EL-4 (EL-4/B7.1) and EG7 (EG7/B7.1) cells. Expression of CD28 on scTCR-modified BW5147 cells led to more than a two-fold increase in maximal IL-2 production and lowered the threshold of OVA 257-264 peptide concentration needed for scTCR-induced activation to 10 À8 M (IL-2: 133 pg/ml, backgroundo10 pg/ml) (Fig 3d) . A similar enhancement effect of CD28 was observed in flTCR-modified BW5147 cells, but was more significant when the OVA 257-264 peptide concentration was low (10 À10 M or less). To insure that B7.1 gene transfer had no direct effect on antigen presentation capacity, flTCR-reconstituted CD28 negative BW5147 cells were cocultured with 
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OVA 257-264 -pulsed EL-4 or EL-4/B7.1 cells. There was no significant difference in IL-2 production using either cell line, indicating that both EL-4 and EL-4/B7.1 cells were comparable in OVA peptide presentation. Therefore, the dramatic increase in IL-2 production observed with CD28 þ TCR-transduced BW5147 and EL-4/B7.1 cells was due to the interaction between CD28 and B7.1. Despite the dramatic enhancement effects of CD8 and CD28, none of the scTCR-modified BW5147 cells were able to respond to OVA-expressing EG7 cells, whereas 2.2-7.3% (147733-497718 pg/ml, background o20 pg/ ml) of the maximal IL-2 production was observed 
TCR-transduced primary T cells are functional
The ultimate goal of this methodology is to use TCR gene-modified T cells for adoptive immunotherapy. Thus, it is critical to test the functional efficiency of these TCR molecules (both scTCRs and flTCRs) expressed on primary T cells. Cell surface expression of OVA-specific scTCRs and flTCR on transduced primary T lymphocytes was determined using PE-anti-Va2 mAb (Fig 4) . In mocktransduced T cells, the percentage of Va2 þ T cells was 30%, whereas more than 90% of OT1 T cells expressed Va2. Transgenic expression of both scTCR and flTCR constructs varied from 10 to 40% estimated by deduction of the background value (30%) from the actual level of Va2 expression. Similar to the IL-2 production observed in BW5147 cells, significant IFN-g production by scTCRtransduced primary T cells was observed after OVA [257] [258] [259] [260] [261] [262] [263] [264] peptide stimulation (Table 2) . However, the threshold of IFN-g production by scTCR-modified primary T cells was 2-log lower than that of IL-2 release by BW5147 cells, although scTCR expression on primary T cells was lower. Similar to scTCR-modified BW5147 cells, scTCR-transduced primary T cells still failed to respond to the stimulation of EG7 cells. In contrast, flTCR-modified primary T cells produced extraordinary amounts of IFN-g comparable to OT1 T cells after stimulation with a low concentration of OVA peptide (10 À10 M) and EG7 cells. The cytotoxic activity of TCR-modified splenic T cells was also tested (Fig 5) . flTCR-transduced primary T cells demonstrated a level of cytotoxicity against OVA-loaded EL-4 cells similar to OT1 CTL, but were less efficient in killing EG7 cells. In all tested scTCRs, scTCR-z-28-Lck was the most effective in allowing transduced T cells to Transgenic TCR expression T Zhang et al lyse OVA-pulsed EL-4 cells, whereas other scTCRs endowed primary T cells with only moderate cytolytic capacity even when antigen density on target cells was high (10 -6 M). In addition, IFN-g production was correlated with the level of cytotoxic activity in TCRtransduced T cells.
Discussion
An increased understanding of TCR recognition of the MHC-peptide complex and the subsequent signal transduction events has permitted a rational design of TCRbased chimeric receptors for immunotherapy. A promising 3D-scTCR candidate should meet three requirements. First, it should be efficiently expressed on the cell surface. Second, it should recognize the MHC-peptide complex with fine specificity and transduce signals efficiently. Third, it should not be highly immunogenic. 10 Therefore, after being applied in vivo, no significant immune responses should be elicited, which might compromise the efficiency of scTCR-modified T cells. In the present study, our focus was on the exploration of the relationship between scTCR structure and function as well as surface expression.
Two scTCR constructs containing the TCR Cb as the TM region had poor cell surface expression on the nonlymphoid NIH-3T3 cell-based packaging cell, GP þ E86. This fact may be because the TM region of the TCR is responsible for assembly with the CD3 complex (not expressed on nonlymphoid cells) for surface expression. 13, 14 In contrast, scTCRs with the TM region derived either from CD3z or CD28 could be efficiently expressed on GP þ E86 cells as well as on the CD3d
À z À T cell line BW5147, indicating that the complete CD3 complex was not indispensable for membrane expression of such scTCRs. Such a CD3 complex-independent nature allows scTCR constructs to be expressed at high levels after multiple transductions, whereas transgenic fulllength TCR expression on BW5147 cells was constant due to its dependence on the presence of other components of the CD3 complex. This finding may pose a potential problem for the genetic modification of primary T cells from tumor patients using full-length TCRs because these T cells generally have a reduced level of CD3z expression, 16 thereby affecting transgenic TCR expression. Fusion of the CD28 cytoplasmic tail to the Cterminal end of CD3z dramatically reduced cell surface expression. A similar finding has been reported previously. 3, 25 However, inefficient surface expression could be completely rescued by addition of the Lck kinase to the carboxyl end of the aforementioned molecule. Although the TM region of B7.1 has been shown to be efficient in directing cell surface expression, 29 no significant advantage over that with CD3z or CD28 was observed.
A recent study by Holler et al 30 has clearly shown that CD8 has significant synergistic effects on TCR-MHCpeptide interactions when the affinity of the TCR is within low or medium ranges. Two roles for CD8 have been suggested in promoting T-cell activation. 31 First, CD8 binds to MHC, although with a very low affinity (K: 50-200 mM). Second, an Src-family kinase Lck, which is constitutively associated with the CD8a chain, is recruited to the TCR:CD3 complex after initial triggering, thereby enhancing TCR triggering by stabilizing the TCR:peptide-MHC interaction and/or amplifying signaling. Previous studies have shown that scTCR molecules have a lower affinity compared with parental full-length TCRs. 17, 19 Therefore, CD8 might be more helpful in this case. The observation that coexpression of CD8aa and scTCR led to a 30-300% increase in maximal IL-2 production supports this hypothesis. In addition, CD8aa also promoted the function of scTCR-z-28-Lck and scTCR-28-z-Lck, containing the Lck module, suggesting that the second function of CD8 is not the only one mediating the enhancement effect.
CD28 provides very potent costimulation, but requires stimulator cells to express B7, whose expression is restricted to professional antigen-presenting cells (APCs). Combining the CD28 signaling domain with the CD3z chain in a single immunoreceptor allows for T-cell activation through both primary and secondary signals. 3, 25, 32 This strategy avoids the requirement for B7 expression. Our results showed that the CD28-containing scTCRs had a 50-100% increase in maximal IL-2 production in the presence of CD8aa. In view of the lower expression of these constructs compared with scTCR-z (26-53%) on BW5147 cells, the costimulation effects of the CD28 moieties might be more significant. However, CD28 when expressed separately, could provide more potent costimulation to scTCR-as well as fulllength TCR-induced stimulation. Two reasons might be responsible for this phenomenon. First, the CD28 signaling domain in the chimeric H-2K b molecule may not be fully functional. Second, compared with high expression of the wild-type CD28, relatively lower number of CD28 signaling domains are present in the chimeric H-2K b molecule due to its low surface expression leading to limited costimulation.
One interesting finding was that CD28(TM)-containing scTCRs (scTCR-28-z and -28-z-Lck) and scTCR-Cys-z in BW5147 cells demonstrated significant declines in IL-2 production when the OVA peptide concentration decreased from 10 À4 to 10 À6 M. No similar finding was found with primary T cells. A previous study 33 has shown that a chimeric receptor with the TM region from the CD3z chain, when transferred to primary T cells, could form both homodimers and heterodimers of the chimeric receptor with the endogenous z chain. Since BW5147 cells do not express endogenous CD3z and CD28, if CD3z(TM)-and CD28(TM)-containing scTCRs express as a dimer form, it will be as homodimers. Distinct dimer forms of scTCR on primary T cells and BW5147 cells might play a role in the differential sensitivity of scTCR-modified T cells to antigen stimulation. Other factors, such as higher sensitivity of IFN-g release by CTL than IL-2 production in BW5147 cells and exclusive expression of CD8ab rather than the less effective CD8aa on splenic T cells, 34 might also be involved in lower activation thresholds in scTCR-modified primary T cells. Transfer of flTCR genes to primary T cells has been shown to be an effective approach to bestow specificity and function to transduced T cells. Our results, showing that flTCR-modified T cells could respond to antigen stimulation at a sensitivity comparable to natural CTL, were in agreement with these findings. One significant drawback of using flTCR is that the competition between the transgenic and endogenous TCR might reduce the percentage of correct chain pairings, thus limiting the avidity of the resulting TCR-transduced cells. 10, 35 This problem cannot be completely overcome by increasing the gene transfer efficiency and could be more significant when antigen density on target cells is low. 35 Although a 3D-scTCR would allow coordinate expression of TCR Va and Vb chains on the same molecule regardless of endogenous TCRs, the affinity of MHC-peptide recognition by such chimeric receptors may not be optimal as suggested by the low efficiency of scTCR compared to flTCR. It has been shown that TCR affinity for MHC/ peptide complex dictates the threshold of activation. 30 T cells with high-affinity TCR require low antigen density to be activated, whereas low-affinity TCR-expressing T cells require high antigen concentrations to do so. The response threshold of the scTCRs in response to OVA peptide stimulation is much higher (2-3-log) than that seen in flTCR-modified T cells, suggesting that it is likely that the affinity of scTCRs in this study is lower than that of flTCR. To determine whether inefficient recognition of H-2K b -OVA by scTCRs was due to low TCR affinity, an OVA 257-264 -loaded H-2K b -Ig dimer was used to stain the TCR-transduced T cells. However, both flTCR-and scTCR-transduced primary T cells were stained poorly with the dimer (data not shown). In the future, we plan to try an improved tetramer technology 36 to identify the differential affinity between flTCR and scTCR. Holler et al 37 demonstrated that the low affinity of scTCR molecules could be dramatically increased by an in vitro selection system through site-directed mutagenesis. Primary T cells modified with the scTCR-z-28-Lck could lyse low concentrations (10 À10 M) OVA peptide-pulsed EL-4 cells (E:T ¼ 10:1), although at a marginal level. After a moderate improvement of TCR affinity by the in vitro selection system mentioned above, the new version scTCR-z-28-Lck is expected to be a promising candidate in in vivo study.
In summary, we have constructed a series of scTCR molecules containing various TM regions and cytoplasmic signaling domains that allowed us to investigate systematically the impact of scTCR structure on T-cell function. Our results showed that transfer of TCR genes (either scTCRs or flTCR) into T cells bestowed the resulting T cells with both specificity and functional activity. TM regions and signaling domains had dramatic effects on the expression and function of TCR-modified T cells. Expression of scTCRs was CD3 complex-independent. The coreceptor CD8 and costimulatory receptor CD28, but not the CD3 complex, could significantly enhance scTCR-induced T cell activation. However, despite many optimizations, scTCRs were less efficient than flTCR in response to low concentrations of antigen stimulation. This low efficiency of scTCR appears to be due to the inherent low-affinity binding of the receptor.
